6.71

2.60% 0.17

After Hours: 6.74 0.03 +0.45%

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $6.71, with a volume of 66,991. It is up +2.60% in the last 24 hours and down -31.18% over the past month. Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Previous Close:

$6.54

Open:

$6.5

24h Volume:

66,991

Relative Volume:

0.29

Market Cap:

$92.58M

Revenue:

Net Income/Loss:

$-56.20M

P/E Ratio:

-1.8796

EPS:

-3.57

Net Cash Flow:

$-39.97M

1W Performance:

+0.90%

1M Performance:

-31.18%

6M Performance:

+11.83%

1Y Performance:

-19.25%

1-Day Range:

$6.50

$6.75

1-Week Range:

$6.36

$7.52

52-Week Range:

$4.53

$22.49

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	6.71	92.58M	0	-56.20M	-39.97M	-6.22
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

Nov 29, 2024

Annovis Bio Announces Investor Webcast to Share Key Updates - MyChesCo

Nov 29, 2024

Nov 27, 2024

Down Syndrome Market expected to rise | Companies- Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Thera - Barchart

Nov 27, 2024

Nov 25, 2024

Annovis to Host Year-End Investor Webcast on December 11, 2024 - The Manila Times

Nov 25, 2024

Nov 22, 2024

Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) Target Price at $32.17 - MarketBeat

Nov 22, 2024

Nov 20, 2024

Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN

Nov 17, 2024

When the Price of (ANVS) Talks, People Listen - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart

Nov 14, 2024

Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat

Nov 14, 2024

Nov 12, 2024

Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart

Nov 12, 2024

Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo

Nov 12, 2024

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire

Nov 12, 2024

Nov 11, 2024

Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart

Nov 11, 2024

Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times

Nov 11, 2024

Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq

Nov 11, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 11, 2024

Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance

Nov 11, 2024

Nov 08, 2024